[EN] NEW 1-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF<br/>[FR] NOUVEAUX LIGANDS 1-ARYLPIPÉRAZINIQUES DE RÉCEPTEUR 5-HT7 ET UTILISATION DE CEUX-CI
申请人:UNIV BARI
公开号:WO2012159662A1
公开(公告)日:2012-11-29
The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.
I-arylpiperazinic ligands of 5-HT7 receptor and use thereof
申请人:Leopoldo Marcello
公开号:US09260400B2
公开(公告)日:2016-02-16
The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor and having the following formula IV:
wherein W is O;
K, L, M and Q is CH or nitrogen;
R1 is hydrogen;
R2 is hydrogen; and
Ar is an aromatic ring with the following formula:
wherein X, Y and Z is CH; and R3 is a five- or six-membered ring selected from the group consisting of:
New 1-arylpiperazinic ligands of 5-HT7 receptor and use thereof
申请人:Università degli Studi di Bari "Aldo Moro"
公开号:EP2816037A2
公开(公告)日:2014-12-24
The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.
NEW I-ARYLPIPERAZINIC LIGANDS OF 5-HT7 RECEPTOR AND USE THEREOF
申请人:UNIVERSITA' DEGLI STUDI DI BARI ''ALDO MORO''
公开号:US20140086834A1
公开(公告)日:2014-03-27
The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.